In addition to primary resistance mechanisms, the activity of anti-EGFR monoclonal antibodies in CRC is limited by the development of molecular alterations producing acquired resistance [9,10,11,12,13,14,15]. The gene discussed is EGFR; the disease is colorectal carcinoma.